The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing the medication to patients, possibly by summer’s end or early autumn.
It’s a fraught moment, with hope running high for families and other promising therapies such as donanemab on the horizon. Still, medical providers are cautious. “This is an important first step in developing treatments for complex neurodegenerative diseases, but it’s just a first step,” said Ronald Petersen, director of the Mayo Clinic’s Alzheimer’s Disease Research Center in Rochester, Minnesota.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
Health - Latest - Google News
August 11, 2023 at 09:55PM
https://ift.tt/RQPSBA2
New Alzheimer's drug raises hopes — along with questions - Endpoints News
Health - Latest - Google News
https://ift.tt/4TMq1FO
Bagikan Berita Ini
0 Response to "New Alzheimer's drug raises hopes — along with questions - Endpoints News"
Post a Comment